Differential effects of interferon and lamivudine on serum HBV RNA inhibition in patients with chronic hepatitis B

Antiviral Therapy

Volumn 15, Issue 2, 2010, Pages 177-184

  Huang, Yi Wen ^a,b   Chayama, Kazuaki ^c   Tsuge, Masataka ^c   Takahashi, Shoichi ^c   Hatakeyama, Tsuyoshi ^c   Abe, Hiromi ^c   Hu, Jui Ting ^a,d   Liu, Chun Jen ^b   Lai, Ming Yang ^b   Chen, Ding Shinn ^b   Yang, Sien Sing ^a,d   Kao, Jia Horng ^b,e  

^a CATHAY GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c HIROSHIMA UNIVERSITY   (Japan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; INTERFERON; LAMIVUDINE; NUCLEIC ACID; NUCLEOSIDE ANALOG; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA REPLICATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77950681821     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1508     Document Type: Article

References (23)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
2. Kao JH, Chen DS. Overview of hepatitis B and C viruses. In Goedert JJ (Editor). Infectious Causes of Cancer: Targets for Intervention. Totowa: Humana Press 2000; pp. 313-330.
3. McQuilland GM, Townsend TR, Fields HA, Carrol M, Leahy M, Polk BF. Seroepidemiology of hepatitis B virus infection in the United States 1976 to 1980. Am J Med 1989; 87 Suppl 1:S5-S10.
4. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262:369-370.
5. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56:651-693.
6. Lok ASF, McMahon BJ. AASLD practice guidelines. Chronic hepatitis B. Hepatology 2007; 45:507-539.
7. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′- thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991; 88:8495-8499.
8. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
9. 9. Zhang W, Hacker HJ, Tokus M, Bock T, Schroder CH. Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol 2003; 71:24-30 (Pubitemid 37121909)
10. 10. Hatakeyama T, Noguchi C, Hiraga N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology 2007;45:1179-1186. (Pubitemid 46775780)
11. 11. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000; 46:562-568. (Pubitemid 30305823)
12. Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005; 100:2463-2471.
13. 13. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102:96-104. (Pubitemid 46072048)
14. 14. McClary H, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74:2255-2264. (Pubitemid 30091480)
15. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J. Virol 2000; 74:4165-4173.
16. 16. Thomas H, Foster G, Platis D. Mechanisms of action of interferon and nucleoside analogues. J Hepatol 2003; 39:S93-S98. (Pubitemid 37222654)
17. 17. Pasquetto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002; 76:5646-5653. (Pubitemid 34517915)
18. Lengyel P. Mechanisms of interferon action: the 2′5′ A synthetase-RNase L pathway. In Gresser I (Editor). Interferon 3. New York: Academic Press 1981; pp. 77-99.
19. Huang YW, Chayama K, Tsuge M, et al. Serum HBV RNA level reflects the potency of nucleos(t)ide analogue. Hepatol Int 2009; 3:110.
20. 20. Rokuhara A, Matsumoto A, Tanaka E, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol 2006; 41:785-790. (Pubitemid 44446133)
21. 21. Gerelsaikhan T, Tavis JE, Bruss V. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J Virol 1996; 70:4269-4274. (Pubitemid 26187427)
22. 22. Kock J, Theilmann L, Galle P, Schlicht HJ. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology 1996; 23:405-413. (Pubitemid 26087152)
23. Huang YW, Tsuge M, Takahashi S, et al. Interferon inhibits HBV RNA detected during lamivudine therapy. J Hepatol 2008; 48:S244.